MacroGenics, Inc. (MGNX)
After hours:
- Motley Fool
Why MacroGenics Stock Is Tanking Today
Shares of MacroGenics (NASDAQ: MGNX) were tanking by 19.7% as of 12:22 p.m. ET on Wednesday. MacroGenics reported Q1 revenue of $11.1 million, with $3.6 million in sales of breast cancer drug Margenza and the rest from collaborative agreements. It's not surprising that the MacroGenics stock fell after it missed Q1 estimates.
- Zacks
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignanciesConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatme
